BIOMERICA INC FY 2026: Revenue $4.45M, EPS $(1.30) — 10-K Summary
BIOMERICA INC (BMRA) reported FY 2026 revenue of $4.45M, down 16% YoY, and a net loss of $3.78M, improved from $4.97M in FY 2025. EPS was $(1.30), up from $(2.16). Revenue decline was due to lower clinical lab and OTC volumes. The company secured a CPT code and Medicare rate for inFoods® IBS and entered agreements targeting $1.75M in fees.
How this was made
The 30-second read
Why it matters
The earnings release provides the first public numbers for FY 2026, offering traders fresh data to reassess valuation.
Market read
Primary relevance is to traders tracking micro‑cap biotech earnings; broader market impact is limited.
What to watch
Secured CPT PLA code and Medicare rate could improve cash flow if claims volume ramps up.
Background
The article is an AI‑generated summary of Biomerca's FY 2026 10‑K filing, highlighting key financial metrics and recent agreements.
Ticker impact
BIOMERICA INC reported FY 2026 revenue of $4.45M and a narrowed loss of $3.78M, its first earnings disclosure for the period.
Limited upside potential; price may trade sideways or modestly higher on improved loss guidance.
The company is a micro‑cap with small absolute numbers; the improvement in loss is positive but scale is limited.
Market effects
Minimal impact on the broader biotech/clinical‑lab sector; results are company‑specific.
No significant regional effect; company operates primarily in the U.S. and U.K.
Low global relevance due to small market cap and limited revenue.
Counterpoint
Despite narrowed losses, revenue decline may signal longer‑term demand weakness.
Key entities
- CompanyBiomerca Inc.
Micro‑cap biotech/clinical‑lab firm reporting FY 2026 results.
